Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy

Br J Ophthalmol. 2008 Jul;92(7):936-40. doi: 10.1136/bjo.2007.132357.

Abstract

Aims: To clarify vascular changes of polypoidal choroidal vasculopathy (PCV) after photodynamic therapy (PDT).

Methods: Thirty-one eyes underwent PDT with verteporfin and were followed every 3 months with indocyanine green angiography (ICGA) using confocal scanning ophthalmoscope and optical coherence tomography (OCT) for over 15 months and the findings recorded.

Results: The mean follow-up period was 19.2 months. Regression of the polypoidal lesions were confirmed once in 29 eyes (94%) on ICGA and OCT. Some lesions recurred at the initial regions (n = 5 eyes), at different regions connected to the branching vascular network (n = 4 eyes), and at both regions (n = 1 eye) (mean 11.4 (SD 1.9) months) after initial PDT. The branching vascular network remained in all eyes and enlarged in 13 eyes (42%) at the final visit. The vascular features of residual branching vascular networks changed (n = 7 eyes); fibrinous subretinal exudation developed (n = 4 eyes), and the retinal pigment epithelium was elevated similar to vascularised pigment epithelial detachment (n = 3 eyes).

Conclusion: Polypoidal lesions of PCV are treatable with PDT; however, they often recur. The branching vascular networks do not regress and allow the recurrence of polypoidal lesions at the network termini. Alterations of the vascular features may occur; careful observation is needed after PDT.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Choroid / blood supply*
  • Choroid Diseases / drug therapy*
  • Choroid Diseases / physiopathology
  • Female
  • Fluorescein Angiography
  • Follow-Up Studies
  • Humans
  • Indocyanine Green
  • Male
  • Middle Aged
  • Peripheral Vascular Diseases / drug therapy*
  • Photochemotherapy / methods*
  • Photosensitizing Agents / therapeutic use
  • Porphyrins / therapeutic use
  • Prospective Studies
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Verteporfin
  • Visual Acuity

Substances

  • Photosensitizing Agents
  • Porphyrins
  • Verteporfin
  • Indocyanine Green